Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients

Focusing on the unmet medical needs of patients with rare disorders and their families

More

Our Company

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

More

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

More

Latest News

08.06

Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders

Read More
08.06

Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

Read More
07.31

Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

Read More
07.01

Zynerba Pharmaceuticals Added to Russell 2000® and 3000® Indexes

Read More

This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.